Prestodol Compuesto may be considered to provide relief from mild to moderate acute pain. It is often used for situations requiring targeted symptom management, such as discomfort following minor surgical or dental procedures.

The medication can also assist in managing the associated discomfort of various chronic conditions, including musculoskeletal pain, persistent backache, and certain forms of arthritis. It offers supportive care for other painful states like headaches and dysmenorrhea (menstrual cramps). This relief may help support the return of functional ability.

The primary uses of Prestodol Compuesto include the temporary management of pain associated with minor procedures, relief from acute muscle pain, and the reduction of discomfort linked to common conditions like menstrual cramps.

---

Quick Fact: Relief for Acute and Chronic Pain

Eligibility Map: Who can and cannot use Prestodol Compuesto

This section describes the official regulatory restrictions and populations contraindicated for the use of Prestodol Compuesto, based on its known components (Clonixin and Scopolamine Butylbromide).

---

Contraindicated Populations (Must Not Use)

Population Group	Condition/Eligibility Status	Constraint Context
Hypersensitivity	Documented allergy to Clonixin, Scopolamine Butylbromide, or any ingredient.	Risk of severe allergic reaction.
Gastrointestinal	Active or recurrent peptic ulcer; GI bleeding.	Component Clonixin (NSAID) increases risk of serious GI events.
Severe Organ Impairment	Severe liver failure; severe heart failure; severe, uncontrolled renal impairment.	Drug clearance is compromised, increasing toxicity risk.
Certain Clinical States	Third trimester of pregnancy (due to NSAID component); certain types of glaucoma or urinary obstruction (due to antispasmodic component).	Physiological contraindication based on known pharmacology.

---

Age and Other Restrictions

• Pediatric Use: Generally not recommended for use in children under 12 years of age unless specifically advised by a physician, as pediatric safety and efficacy are often not established.
• Pregnancy/Lactation: Use is contraindicated during the third trimester of pregnancy. For other trimesters and during breastfeeding, use is generally not recommended and requires strict risk-benefit assessment, as components can be excreted into breast milk.

Regulatory documents establish that patients with severe functional impairments of the liver, kidney, or heart, or those with certain active bleeding or ulcer conditions, are explicitly excluded from using this medicine due to the significantly increased risk of serious adverse outcomes.

Interactions with other medicines and products: Official Regulatory Information

The interaction profile for Prestodol Compuesto is structured around the two active components, leading to restrictions and documented effects across both pharmacokinetic and pharmacodynamic domains.

Contraindicated Combinations

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is formally prohibited due to the risk of additive gastrointestinal toxicity associated with the Clonixin component. The concurrent use of other Anticholinergic Agents is also prohibited due to the documented potential for potentiating anticholinergic effects, such as urinary retention, caused by the Hyoscine Butylbromide component.

Pharmacokinetic and Pharmacodynamic Effects

Official regulatory documents state that co-administration may increase the systemic exposure of substances such as Lithium and Methotrexate by reducing their renal clearance. This reduction in clearance is a formally documented pharmacokinetic interaction.

In the pharmacodynamic domain, co-use with Anticoagulants increases the documented risk of hemorrhage. Furthermore, the antihypertensive efficacy of Diuretics, ACE Inhibitors, and ARBs may be officially reduced, a constraint that carries a heightened risk of severe renal adverse events in elderly patients.

Alcohol consumption is documented to increase the risk of gastrointestinal bleeding. Mandatory administration separation is required for co-use with Antacids or Adsorbent Agents to prevent a documented reduction in the absorption of the active ingredients.

Prestodol Compuesto is a fixed-dose combination product containing Clonixin Lysinate and Scopolamine Butylbromide (also known as Butylscopolamine or Butylhyoscine). The combined mechanism of action involves modulation of peripheral signal transduction pathways and visceral smooth muscle activity.

Clonixin Lysinate functions as a non-steroidal anti-inflammatory compound. Its primary biological target is the prostaglandin synthetase enzyme system, specifically through non-selective inhibition of cyclooxygenase (COX) activity. This inhibitory interaction blocks the conversion of arachidonic acid into prostaglandins, thereby reducing the concentration of these lipid mediators at peripheral sites.

Scopolamine Butylbromide acts as a synthetic quaternary ammonium antispasmodic agent. Its mechanism is competitive antagonism at peripheral muscarinic cholinergic receptors (mAChRs) located on visceral effector organs, particularly in the gastrointestinal, biliary, and genitourinary tracts. By occupying these receptors, it prevents the binding of the endogenous neurotransmitter acetylcholine, leading to a downstream cascade that inhibits parasympathetic stimulation. This results in the inhibition of smooth muscle tone and peristalsis in these peripheral systems, without significant penetration of the central nervous system due to its chemical structure.

Official Administration Guidelines

Prestodol Compuesto is a fixed-dose combination product containing the non-steroidal anti-inflammatory drug (NSAID) Clonixinato de Lisina and the antispasmodic Hyoscine Butylbromide.

Administration Summary

Administration Scope	Official Instruction
Route of Administration	Oral
Standard Adult Dose	One to two tablets (Clonixinato de Lisina 250 mg / Hyoscine Butylbromide 10 mg)
Frequency and Timing	Up to four times daily (cuatro veces al día)
Preparation Requirements	None. The tablet must be taken intact.
Use-Context Constraint	Requires a medical prescription (venta requiere receta médica)

Procedural Instructions

The medicine must be used exclusively according to medical indication.

1. Obtain the prescribed dose (one or two tablets) from a licensed pharmacist or dispensing facility. The sale is restricted by prescription.
2. Take the tablet(s) by mouth (oral route) up to the maximum labeled frequency of four times a day.
3. Do not exceed the dosage prescribed by the physician.
4. The duration of treatment must be determined by a health professional, and prolonged use without medical control is to be avoided.

Connection to Use Protocol

The established administration guidelines define the required use protocol as a strict, physician-controlled oral regimen. The standardized dosage and frequency provide the maximum labeled limit, while the mandate for professional oversight ensures that the specific number of tablets taken and the overall treatment duration are customized and supervised by a doctor.

Research Evidence / Overview of Studies for Prestodol Compuesto

---

Research Evidence for Pain Associated with Visceral Spasm

Research has explored the use of the medicine’s active components in studies examining outcomes related to physical discomfort linked to involuntary smooth muscle contraction. Studies conducted during periods of increased symptom activity utilized short-term Randomized Controlled Trials (RCTs). These trials were primarily applied in research contexts involving fluctuating or unstable symptoms in adult populations experiencing acute pain episodes.

Researchers examined patient-reported outcomes describing perceived discomfort and measured the time required for the start of perceived symptom change. Research monitored the requirement for rescue analgesia as an outcome measure. Findings describe patterns observed in the studies related to symptom intensity or variability over short defined time intervals. Evidence is generally considered Moderate in this domain.

---

Research Evidence for Menstrual Cramping (Dysmenorrhea)

---

The research base for menstrual cramping (dysmenorrhea) includes studies exploring short-term changes using Randomized Controlled Trials (RCTs) and supporting observational studies. Research examined the medicine’s components in conditions associated with acute or disruptive episodes, focusing on adult women experiencing primary dysmenorrhea. Studies monitored outcomes reflecting daily functioning or activity level during the menstrual cycle.

Findings indicate patterns related to changes in the measured severity of physical discomfort during the study period. The certainty level for this domain is generally described as Moderate.

---

Evidence Gaps and Areas of Scientific Uncertainty

---

The primary limitation in the research base is the lack of extensive, dedicated trials for the specific fixed-dose combination of Clonixin and Hyoscine Butylbromide. Much of the supporting evidence for this dual action is derived from studies where the component agents were evaluated in combination with different active ingredients or as stand-alone treatments.

Long-term effects are not fully established, as follow-up durations were limited to acute episodes. Data for certain groups, such as older adults and those with multiple coexisting health conditions, remain insufficient. These limitations indicate that while the components have been observed in studies exploring how symptoms change over time, the certainty remains low for long-term personalized outcomes.

Common questions about Prestodol Compuesto (FAQ)

Q: How quickly does Prestodol Compuesto usually start to work?

Studies conducted on the medicine's active components have monitored the time it takes for patients to notice the start of changes in their symptoms. This indicates that the onset of effect is a monitored factor in the clinical research that supports the medicine's use.

Q: What is the expected duration of the effects of Prestodol Compuesto?

The official product information specifies a maximum frequency of administration of up to four times daily. This schedule implicitly defines the expected timeframe of the medicine's effect, based on the dosing regimen approved by regulatory bodies.

Q: Why do people sometimes say Prestodol Compuesto makes them feel sleepy?

The active component, Hyoscine Butylbromide, has documented effects in regulatory materials. These official documents note that sleepiness (somnolence) is a possible effect, though it is typically reported as an uncommon adverse reaction.

Q: Are there any common foods or drinks that should be avoided when taking Prestodol Compuesto?

Official regulatory information documents a specific constraint regarding the consumption of alcohol. Taking this medicine with alcohol is noted to increase the documented risk of gastrointestinal bleeding.

Q: Can elderly patients generally use Prestodol Compuesto?

Regulatory labeling notes that older adults should use the medicine with caution. This is because they may be at an increased risk of certain adverse events, such as anticholinergic side effects or serious gastrointestinal events. Use in this population group is managed under the direction of a health professional.

Q: Is Prestodol Compuesto classified as a narcotic or controlled substance?

No, the medicine is classified as a combination of a non-steroidal anti-inflammatory drug (NSAID) and an anticholinergic spasmolytic. The active components are not classified as narcotics or controlled substances by major regulatory bodies.

Q: Can Prestodol Compuesto affect my ability to drive or operate machinery?

Official regulatory documents list potential side effects that may impact activities requiring full attention. These include common effects like dizziness and uncommon vision disorders, such as disturbances in accommodation (the eye's ability to focus).

Q: Can Prestodol Compuesto be used for chronic conditions?

Official administration guidelines advise against prolonged use without medical control. Additionally, regulatory documents confirm that the long-term effects of this specific combination product are not fully established in the available research, as studies were often limited to acute episodes.

Q: Does Prestodol Compuesto contain caffeine or other stimulants?

The active components listed in the official regulatory documents are Clonixin (a pain reliever and anti-inflammatory) and Hyoscine Butylbromide (an antispasmodic). No other stimulants, such as caffeine, are listed as active ingredients in the product formulation.

Q: Does taking Prestodol Compuesto affect sleep patterns?

Regulatory information notes certain effects related to the central nervous system (CNS). These include common effects like dizziness and, for one component, less common effects like sleepiness (somnolence), which can be a factor that influences sleep patterns.

Q: Does Prestodol Compuesto contain aspirin?

No, the active ingredients listed in official product information are Clonixin and Hyoscine Butylbromide. Aspirin (acetylsalicylic acid) is a chemically distinct substance and is not an active component in the formulation.

Q: What is the risk of dependence or addiction with Prestodol Compuesto?

The medicine is not classified as a narcotic or a controlled substance. Official regulatory information for the antispasmodic component (Hyoscine Butylbromide) indicates a low incidence of abuse risk, as its action is primarily peripheral and does not significantly penetrate the central nervous system.

The official storage and disposal guidelines for this medicine, which combines Clonixin and Hyoscine Butylbromide, define specific conditions for product stability and safety. The product must be stored at a temperature that does not exceed 30 C (e.g., source 3.1). Storing at higher temperatures is prohibited to prevent deterioration.

Regulatory requirements mandate that all forms of this medicine must be kept in a safe place, out of the sight and reach of children, to prevent accidental ingestion (e.g., source 3.2).

Packaging integrity is critical; the product must not be used after the printed expiry date on the blister or carton. When disposing of unused or expired medicine, it must not be thrown away via wastewater or household trash. Patients are instructed to consult a pharmacist or local regulatory body for guidance on proper pharmaceutical disposal methods, ensuring protection of the environment (e.g., source 3.2).